SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 1, 2005
IntraBiotics Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
| | | | | |
| Delaware | | 0-29993 | | 94-3200380 |
| |
(State or other jurisdiction
of incorporation) | | (Commission File Num | | ber) (IRS Employer Identification No.) |
1009 Oak Hill Road, Suite 201
Lafayette, CA 94549
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code:(925) 906-5331
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (seeGeneral Instruction A.2. below):
| o | | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
| o | | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
| o | | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
| o | | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.02(b).Departure of Directors or Principal Officers;
On December 1, 2005, Mr. Mark L. Perry provided IntraBiotics Pharmaceuticals, Inc. (the “Company”) with a notice of resignation from the Company’s Board of Directors and all committees of the Board effective as of such date.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| | | | | |
| | INTRABIOTICS PHARMACEUTICALS, INC.
| |
| Date: December 6, 2005 | By: | /s/ Denis Hickey | |
| | | Denis Hickey | |
| | | Chief Executive Officer and Chief Financial Officer | |
| |
